Potentiation of alkylating chemotherapy by dual function nitrofurans in multi-cell spheroids and solid tumors.
The cytotoxicity and chemosensitizing potential of four dual function nitrofurans was determined in human HT-29 multi-cell spheroids and rodent KHT sarcoma solid tumors. Spheroids were treated with a range of doses of the bioreductive drugs for a period of up to 48 h and the extent of cell kill was assessed at various times after treatment. Cytotoxicity was determined using a clonogenic cell-survival assay. The results demonstrated that two of the nitrofurans were even more toxic to spheroid cells than was the potent bioreductive nitroimidazole aziridine RSU 1069. The dose of the nitrofuran which, after a 24-h exposure, led to a survival value between 0.5 and 1.0, then was chosen for subsequent studies aimed at assessing the ability of these agents to potentiate the efficacy of the nitrosourea CCNU. Exposure to this chemotherapeutic agent was for a period of 1 h. The results indicated that all four dual function nitrofurans enhanced the cell killing of the conventional chemotherapeutic agent by factors ranging from 1.1 to 1.7. Subsequent studies evaluated the therapeutic benefit of combining these bioreductive agents and CCNU in KHT sarcoma-bearing C3H/HeJ mice. The nitrofurans were administered i.p. 0.5 h prior to the chemotherapy and tumor response was assessed by measuring the survival of clonogenic KHT cells 22-24 h after treatment. Normal tissue toxicity was determined using a bone marrow stem cell (CFU-GM) assay. Combining these bioreductive agents with CCNU increased the tumor cell kill by factors of 1.2 to 1.7.(ABSTRACT TRUNCATED AT 250 WORDS)
Siemann
D W
DW
Tumor Biology Division, University of Rochester Cancer Center, New York 14642.
Sutherland
R M
RM
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001388:Aziridines / Q000627:therapeutic use; D001853:Bone Marrow / Q000187:drug effects* / Q000528:radiation effects; D002277:Carcinoma / Q000188:drug therapy* / Q000532:radiotherapy; D002470:Cell Survival; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D005260:Female; D006801:Humans; D008130:Lomustine / Q000627:therapeutic use*; D051379:Mice; D008809:Mice, Inbred C3H; D008815:Mice, Inbred Strains; D008920:Misonidazole / Q000031:analogs & derivatives / Q000627:therapeutic use; D009581:Nitrofurans / Q000627:therapeutic use*; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use*; D012513:Sarcoma, Experimental / Q000188:drug therapy* / Q000532:radiotherapy; D013234:Stem Cells / Q000187:drug effects / Q000528:radiation effects; D014407:Tumor Cells, Cultured
C049944:1-(2-nitro-1-imidazoly)-3-(2,3-dimethylaziridino)-2-propanol; D000970:Antineoplastic Agents; D001388:Aziridines; D009581:Nitrofurans; C066400:RB 88712; D011838:Radiation-Sensitizing Agents; C073475:2,3-epoxypropyl-5-nitrofuran-2-carboxylate; C073476:N-(2,3-epoxypropyl)-3-(5-nitrofuran-2-yl)-propenamide; C066399:RB 88716; D008130:Lomustine; C041712:1-(2-nitro-1-imidazolyl)-3-aziridino-2-propanol; D008920:Misonidazole